<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ARYA Atheroscler</journal-id><journal-id journal-id-type="iso-abbrev">ARYA Atheroscler</journal-id><journal-id journal-id-type="pmc-domain-id">1701</journal-id><journal-id journal-id-type="pmc-domain">aryaath</journal-id><journal-id journal-id-type="publisher-id">ARYA</journal-id><journal-title-group><journal-title>ARYA Atherosclerosis</journal-title></journal-title-group><issn pub-type="ppub">1735-3955</issn><issn pub-type="epub">2251-6638</issn><publisher><publisher-name>Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11913457</article-id><article-id pub-id-type="pmcid-ver">PMC11913457.1</article-id><article-id pub-id-type="pmcaid">11913457</article-id><article-id pub-id-type="pmcaiid">11913457</article-id><article-id pub-id-type="pmid">40103623</article-id><article-id pub-id-type="doi">10.48305/arya.2025.43212.3007</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effectiveness and medication adherence in patients with ST- elevated myocardial infarction: Persian polypill study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Amirfar</surname><given-names initials="E">Elaheh</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff12" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shirvani</surname><given-names initials="E">Ehsan</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff12" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghaffari Hoseini</surname><given-names initials="S">Shervin</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mansourian</surname><given-names initials="M">Marjan</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aminzadeh</surname><given-names initials="S">Shima</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jamalian</surname><given-names initials="M">Marjan</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nateghi</surname><given-names initials="A">Alireza</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Amirpour</surname><given-names initials="A">Afshin</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>kermani-Alghoreaishi</surname><given-names initials="M">Mohammad</given-names></name><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teimouri-Jervekani</surname><given-names initials="Z">Zahra</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Najafian</surname><given-names initials="J">Jamshid</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanei</surname><given-names initials="H">Hamid</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khosravi-Farsani</surname><given-names initials="A">Alireza</given-names></name><xref rid="aff9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heshmt-ghahdarijani</surname><given-names initials="K">Kiyan</given-names></name><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Askari</surname><given-names initials="M">Mozhdeh</given-names></name><xref rid="aff11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sahebzadeh</surname><given-names initials="M">Mohammadsadegh</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sarrafzadegan</surname><given-names initials="N">Nizal</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roohafza</surname><given-names initials="H">Hamidreza</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names initials="M">Masoumeh</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2">
<label>2</label>Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3">
<label>3</label>Department of Physical Medicine and Rehabilitation, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff4">
<label>4</label>Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff5">
<label>5</label>Chamran Cardiovascular Medical and Research Hospital, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff6">
<label>6</label>Digestive Disease Research Institute, Tehran University of medical Sciences, Tehran, Iran</aff><aff id="aff7">
<label>7</label>Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff8">
<label>8</label>Advara Heartcare, Bundaberg Base Hospital, Bundaberg, Queensland, Australia</aff><aff id="aff9">
<label>9</label>Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff10">
<label>10</label>Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff11">
<label>11</label>Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United States</aff><aff id="aff12">
<label>*</label> These authors contributed equally as First author</aff><author-notes><corresp id="cor">Address for correspondence: Hamidreza Roohafza, MD and Masoumeh Sadeghi, MD. Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; Email: hroohafza@gmail.com, sadeghimasoumeh@gmail.com</corresp></author-notes><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>20</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">484374</issue-id><fpage>43</fpage><lpage>53</lpage><history><date date-type="received"><day>18</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>18</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-19 09:25:20.950"><day>19</day><month>03</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ARYA-20-043.pdf"/><abstract><sec><title>BACKGROUND:</title><p>Polypill or fixed-dose combination has been recognized as an effective secondary prevention strategy for patients with cardiovascular disease (CVD). This study aimed to evaluate the effectiveness of the polypill on one-year medication adherence, patient satisfaction, and lipid profile control in patients with ST-elevation myocardial infarction (STEMI).</p></sec><sec><title>METHODS:</title><p>This was an open-label, multicentric, randomized clinical trial study of STEMI patients who were prescribed a polypill (Aspirin 81 mg, Atorvastatin 40 mg, Metoprolol Succinate 47.5 mg, and Valsartan 40 mg) versus usual care (continued with separate medications) for secondary prevention. The primary outcome was to compare one-year medication adherence between groups. Other outcomes included comparing patient satisfaction and lipid profile after 12 months of follow-up, as well as identifying predictor factors of medication adherence.</p></sec><sec><title>RESULTS:</title><p>Of 624 STEMI participants, 289 patients were treated with the polypill (79.2% male; mean age 61.67 &#177; 8.54 years), and 335 patients received usual care (82.7% male; mean age 62.10 &#177; 9.63 years). After one-year follow-up, no significant differences were detected between groups regarding medication adherence (p-value = 0.351) and cholesterol levels (p-value = 0.808). The polypill strategy was associated with increased patient satisfaction and better control of LDL-C (p-value = 0.043) and HDL-C (p-value &lt; 0.001). Patients with a history of chronic kidney disease (OR: 13.392; p-value = 0.001), cerebrovascular disease (OR: 4.577; p-value = 0.011), and higher waist circumference (OR: 1.01; p-value = 0.002) demonstrated a lower probability of medication adherence. In contrast, in-hospital complications such as arrhythmia (OR: 0.039; p-value = 0.010), bleeding (OR: 0.034; p-value = 0.007), and higher ejection fraction (OR: 0.965; p-value = 0.002) were associated with a higher probability of medication adherence.</p></sec><sec><title>CONCLUSION:</title><p>In STEMI patients, participants treated with polypills were more satisfied and showed better lipid profile control. However, a longer follow-up duration is needed to examine the effectiveness of the polypill on medication adherence in this subgroup.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Polypill</kwd><kwd>ST Elevation Myocardial Infarction</kwd><kwd>Medication Adherence</kwd><kwd>Patient Satisfaction</kwd><kwd>Lipids</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>ST-segment elevation myocardial infarction (STEMI), which accounts for approximately 30% of patients presenting with acute coronary syndrome (ACS), is a clinically time-sensitive fetal condition that results from complete thrombotic occlusion of the infarct-related artery<sup><xref rid="B1" ref-type="bibr">1</xref></sup><sup>,</sup><sup><xref rid="B2" ref-type="bibr">2</xref></sup>. Early reperfusion by percutaneous coronary intervention (PCI) or thrombolytic therapy is the gold standard of treatment for STEM<sup><xref rid="B3" ref-type="bibr">3</xref></sup>. Despite advancements in long-term survival following STEMI, patients still encounter a heightened risk of recurrent myocardial infarction (MI), stroke, and mortality, particularly in the presence of additional risk factors such as diabetes and hypertension<sup><xref rid="B4" ref-type="bibr">4</xref></sup>. This underscores the importance of a secondary prevention strategy targeting standard modifiable cardiovascular risk factors<sup><xref rid="B5" ref-type="bibr">5</xref></sup>.</p><p>Lipid-lowering drugs, anti-hypertensive agents, and anti-platelet therapy are the guideline-recommended pharmacological treatments for secondary prevention in patients with STEMI<sup><xref rid="B6" ref-type="bibr">6</xref></sup>. Despite the proven benefits of evidence-based pharmacological secondary prevention, lack of medication adherence remains a significant challenge in STEMI patients due to the complexity of multi-drug prescriptions. Previous studies have shown that adherence to pharmacotherapy was suboptimal in patients after hospital discharge for STEMI<sup><xref rid="B7" ref-type="bibr">7</xref></sup><sup>,</sup><sup><xref rid="B8" ref-type="bibr">8</xref></sup>, and medication non-adherence was associated with an increased risk of cardiovascular hospitalizations and mortality, coronary revascularization procedures, and increased costs<sup><xref rid="B9" ref-type="bibr">9</xref></sup><sup>,</sup><sup><xref rid="B10" ref-type="bibr">10</xref></sup>.</p><p>Wald et al. first described the polypill strategy, which includes combined pharmaceutical components to simultaneously target major cardiovascular risk factors, for both primary and secondary prevention<sup>11</sup>. The concept of the polypill or fixed-dose combination (FDC) has evolved over time to enhance medication adherence and manage CV risk factors. However, several previous studies have provided moderate evidence that the polypill can improve adherence and CV risk factor control in patients with CVD<sup><xref rid="B12" ref-type="bibr">12</xref></sup><sup>-</sup><sup><xref rid="B17" ref-type="bibr">17</xref></sup>. Still, there is a lack of evidence regarding the effectiveness of the polypill in patients with STEMI. Therefore, our study aimed to compare one-year medication adherence, patient satisfaction, and lipid profile control in STEMI patients treated with the polypill versus usual care.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Design</title><p>This was an open-label, multicentric, parallel two-arm, 1:1 allocation randomized clinical trial of polypill treatment compared with usual care in patients with STEMI for 12 months in three referral hospitals (Chamran, Alzahra, and Khorshid) in Isfahan, Iran. This trial has been registered in ClinicalTrials.gov as Persian Polypill Study (Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03541109">NCT03541109</ext-link>). </p></sec><sec><title>Study Participants</title><p>The study included men and women aged over 40 years who were hospitalized in the mentioned hospitals because of their first episode of STEMI, with a clear indication of receiving all components of the polypill (aspirin, statin, ARB/ACE inhibitor, and beta-blocker) and lived in Isfahan city or nearby areas. The indication for drugs was determined by the responsible physician according to the standard guidelines. Patients with mental illness limiting their self-care ability, severe disease with an estimated lifespan of less than 3 years, history of adverse reaction or contraindication to any component of the polypill, secondary hyperlipidemia, serum creatinine &#8805; 2 mg/dl, severe heart failure, childbearing potential, or planning for a procedure (Coronary Artery Bypass Graft Surgery (CABG), PCI, or another surgical procedure) within the following 6 months were excluded from the study.</p></sec><sec><title>Study Randomization</title><p>Central randomization was used in this study. Blocked randomization with a block size of 5 was used for random sequence generation. An investigator was responsible for randomization, recording a list of patients, and the management of follow-up visits. Responsible physicians in the hospitals assessed patients for eligibility criteria and after obtaining informed consent, they contacted the investigator for the type of intervention allocation. Blinding of investigators and patients was not possible in this study; however, the statistician was blind to the group assignment.</p></sec><sec><title>Intervention</title><p>The polypill used in this study was available in fixed doses of Aspirin (81mg), Atorvastatin (40mg), Metoprolol Succinate (47.5mg), and Valsartan (40mg) (prepared by Alborz Daroo Company). The usual care group received regular drug orders at the time of discharge from the hospital. The responsible physician initiated a regimen of polypill drugs in accordance with the current guidelines<sup><xref rid="B18" ref-type="bibr">18</xref></sup>. If necessary, he/she had the option to switch to a different group of drugs or add a new medication to achieve the treatment objectives. If a patient from the polypill group had been taking any of the four drug classes before hospitalization, the physician could switch to polypill treatment or add individual doses to achieve the desired level of effectiveness. The polypill and those four drug classes were free of charge in this study and were provided to the patients by an individual blind to the two distinct groups.</p></sec><sec><title>Outcomes</title><p>The primary outcome was to compare the one-year adherence of patients to prescribed medication(s) between the polypill and usual care groups. Additionally, the study aimed to compare patient satisfaction as a secondary outcome. Other outcomes included comparing changes in lipid profile between groups after 12 months and identifying factors associated with medication adherence.</p></sec><sec><title>Data Collection Methods and Assessments.</title><p>
<italic toggle="yes">Baseline Characteristics</italic>
</p><p>Baseline demographics (age, sex, marital status, and educational levels), clinical data (past history and family history of diseases, type of treatment, in-hospital complications), and laboratory investigations were collected for each participant using checklists. Waist circumference (WC) and ejection fraction (EF) were collected using appropriate tools and added to the checklist. WC was measured at the narrowest part of the torso between the iliac crest and the xiphoid process or the level of the iliac crest after normal exhalation. EF was determined by a cardiologist using the Philips IE 33 ultrasound machine in the left lateral decubitus position and assessed according to the guidelines<sup><xref rid="B19" ref-type="bibr">19</xref></sup>.</p></sec><sec><title>Medication Adherence Assessments</title><p>The Persian version of the Morisky Medication Adherence Scale (MMAS-8) was used to assess patients&#8217; adherence to medication(s)<sup><xref rid="B20" ref-type="bibr">20</xref></sup>. It consisted of 8 self-reported questions measuring to what extent the patients follow their doctor&#8217;s instructions on medication(s) uptake (seven questions with two-choice answers (yes/no) and one Likert question). For the first 7 questions, a score of 0 was given for each &#8220;yes&#8221; answer and 1 for each &#8220;no&#8221; answer, except for question 5, which was scored in reverse. Question 8 was a 5-point Likert scale, where &#8220;never&#8221; = 0, &#8220;rarely&#8221; = 1, &#8220;sometimes&#8221; = 2, &#8220;often&#8221; = 3, and &#8220;always&#8221; = 4. The total scores ranged from 0 to 8. In this study, scores &gt; 6 were considered good adherence to medication treatment. </p></sec><sec><title>Patient Satisfaction Assessments</title><p>The Treatment Satisfaction Questionnaire for Medication (TSQM) was used to evaluate patient satisfaction with drug treatment over the previous 2-3 weeks or since the patient&#8217;s last use. The TSQM comprised 14 items across four domains: effectiveness (three items), side effects (five items), convenience (three items), and global satisfaction (three items). The patients&#8217; responses were evaluated using a 5- or 7-point Likert scale, except for question four in the side effects domain, which required a simple yes or no answer. If the response to question 4 was negative, questions 4 to 8 in the side effects domain were not asked. A higher score indicated that patients were more satisfied with their drug treatment. The Persian version of the TSQM has shown acceptable validation and reliability results<sup><xref rid="B21" ref-type="bibr">21</xref></sup>. </p></sec><sec><title>Lipids Assessments</title><p>Blood sampling and analysis were done in the hospital laboratories for lipid profile (total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C)) after 10 hours of fasting at night. </p></sec><sec><title>Trial Procedures</title><p>Each participant was followed up for at least 12 months. Laboratory tests, lipid profiles, and questionnaires were obtained six months after recruitment, and at the end of the study.</p></sec><sec><title>Ethical Statement</title><p>The ethics committee of Isfahan University of Medical Sciences approved the informed consent (approval number: IR.NIMAD.REC.1396.24). The study was conducted in accordance with the Declaration of Helsinki. </p></sec><sec><title>Statistical Analysis</title><p>Quantitative variables were presented as mean &#177; standard deviation (SD), and qualitative variables as numbers and percentages (%). The normality assumption was assessed using the Kolmogorov-Smirnov test, with a p-value &lt; 0.05 indicating that the variable did not meet the normality assumption. We used the independent sample t-test and Mann-Whitney test to assess quantitative variables, while categorical variables were compared using the Chi-square test (or Fisher&#8217;s exact test when appropriate). Variables significantly associated with medication adherence in these analyses were examined using logistic regression, reporting the odds ratios (OR) and confidence intervals (CI) for predictive variables. Good adherence is reference variable. Statistical analysis was performed using IBM SPSS (IBM Corporation, Armonk, NY, USA) statistics for Windows version 20 and was considered significant when the p-value was &lt; 0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Baseline Characteristics</title><p>A total of 624 patients with STEMI (81.1% male; mean age 61.90 &#177; 9.14 years) who met the inclusion and exclusion criteria were screened: 289 patients treated with polypill (79.2% male; mean age 61.67 &#177; 8.54 years) and 335 patients with usual care (82.7% male; mean age 62.10 &#177; 9.63 years). At baseline, patients treated with polypill had higher WC (100.60 &#177; 11.62 vs 93.39 &#177; 17.40 cm; p-value &lt; 0.001), HDL-C (41.09 &#177; 7.97 vs 39.38 &#177; 6.82 mg/dl; p-value = 0.002) and lower LDL-C (101.86 &#177; 22.34 vs 106.54 &#177; 26.40 mg/dl; p-value = 0.028) than patients with usual care. The baseline characteristics of study participants are shown in <xref rid="T1" ref-type="table">Table 1</xref>.</p></sec><sec><title>Medication Adherence and Patient Satisfaction Comparison</title><p>At the end of the study, 247 patients (39.58%) were good adherence to medical treatment. One-year medication adherence was similar between the polypill (6.9%) and the usual care group (8.1%) (p-value= 0.351). Patients treated with polypill showed significantly higher satisfaction, especially in the convenience (13.15 &#177; 1.78 vs 12.23 &#177; 1.45; p-value &lt; 0.001) and global satisfaction (13.06 &#177; 1.97 vs 12.75 &#177; 1.18; p-value &lt; 0.001) domains of TSQM (<xref rid="T2" ref-type="table">Table 2</xref>). It is important to note that the adverse effects domain score was also higher in the polypill group than in the usual care group (5.65 &#177; 6.05 vs 2.95 &#177; 2.75; p-value &lt; 0.001). </p></sec><sec><title>Lipid Profile Comparison</title><p>At the end of the study, the polypill group showed higher HDL-C (41.40 &#177; 19.90 vs 37.92 &#177; 7.6 mg/dl; p-value &lt; 0.001) and lower LDL-C (77.06 &#177; 17.31 vs 82.89 &#177; 58.01 mg/dl; p-value = 0.043) than patients in the usual care group (<xref rid="T2" ref-type="table">Table 2</xref>). However, there was no significant difference in cholesterol levels between groups (144.57 &#177; 26.86 vs 144.19 &#177; 41.60 mg/dl; p-value = 0.808).</p></sec><sec><title>Factors Associated with Medication Adherence</title><p>Using a Multilevel Logistic Regression, a lower probability of adherence was observed in patients with a history of cerebrovascular diseases (OR (95% CI): 4.577 (1.410-14.860); p-value = 0.011), history of CKD (OR (95% CI): 13.392 (2.827-63.435); p-value = 0.001), and patients with higher WC (OR (95% CI): 1.01 (1.004-1.035); p-value = 0.002). In contrast, in-hospital complications such as atrial tachyarrhythmia (OR (95% CI): 0.039 (0.003-0.458); p-value = 0.010) and bleeding (OR (95% CI): 0.034 (0.003-0.399); p-value = 0.007) and higher EF (OR (95% CI): 0.957 (0.930-0.984); p-value = 0.002) were associated with a higher probability of medication adherence (<xref rid="T3" ref-type="table">Tables 3</xref> and <xref rid="T4" ref-type="table">4</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>To the best of our knowledge, this was the first study to investigate medication adherence, patient satisfaction, and CV risk factor control in patients with STEMI using either a polypill or usual care for secondary prevention. The study found that medication adherence and cholesterol levels were similar between groups after 12 months. However, patients receiving polypill treatment showed higher satisfaction and better lipid profile control compared to those receiving usual care at the end of the study. Additionally, it was demonstrated that a history of CKD, a history of cerebrovascular disease, EF, WC, and in-hospital complications were independent predictors of medication adherence.</p><p>The results of our study showed that fewer than forty percent of the participants adhered to their medical treatment, and the one-year medication adherence rate was similar between the polypill and usual care groups. Castellano et al. conducted a randomized clinical trial, SECURE trial, comparing the efficacy of the polypill-based strategy with the usual care for secondary prevention in patients with MI<sup>22</sup>. The previous RCT reported significant improvement in medication adherence after 6 months in patients receiving polypills compared with patients in the usual care group (70.6 % vs 62.7%; risk ratio (95% CI): 1.13 (1.06-1.20)). At 24 months, medication adherence also increased in the polypill group more than usual care group (74.1% vs 63.2%; risk ratio (95% CI): 1.17 (1.10-1.25))<sup><xref rid="B22" ref-type="bibr">22</xref></sup>. </p><p>One possible explanation for the discrepancy in our study could be the characteristics of the participants, as patients with STEMI showed lower adherence rates to optimal medication treatment for secondary prevention<sup><xref rid="B23" ref-type="bibr">23</xref></sup>. Additionally, the relatively low adherence rate observed in both groups in our study may be attributed to the novelty of the polypill concept in our region, which might influence patients&#8217; acceptance of the medication. Factors affecting the acceptance of the polypill could include personal beliefs regarding the ineffectiveness of a single pill to manage risk factors such as hyperlipidemia and hypertension, concerns about potential adverse events, and a lack of substantial evidence supporting its effectiveness in preventing cardiovascular events<sup><xref rid="B24" ref-type="bibr">24</xref></sup>. Furthermore, differences in the duration of follow-up and physicians&#8217; concerns regarding the effectiveness of the polypill, which led to discontinuing its use, could explain the differences with the previous study.</p><p>In terms of patient satisfaction, our results showed that patients treated with the polypill were more satisfied than the usual care group, with significantly higher scores in the convenience and global satisfaction domains of TSQM. These findings were consistent with the Aurora study, which also showed that polypill patients reported higher satisfaction in effectiveness, convenience, and global satisfaction compared to patients treated with monocomponents<sup><xref rid="B25" ref-type="bibr">25</xref></sup>. Our findings regarding patient satisfaction align with those of a comparative study evaluating satisfaction levels between a cardiovascular polypill and separate pills. The study demonstrated a significantly higher degree of satisfaction with polypill therapy, and a high proportion of patients receiving the individual components stated that they would prefer the polypill<sup><xref rid="B17" ref-type="bibr">17</xref></sup>.</p><p>Dyslipidemia is a major modifiable risk factor for CVD<sup><xref rid="B26" ref-type="bibr">26</xref></sup>. Previous studies have demonstrated that an increase in triglycerides, total cholesterol, LDL-C, and a decrease in HDL-C are significantly correlated with the risk of CVD<sup><xref rid="B27" ref-type="bibr">27</xref></sup>. Due to perceptions of various medications among patients with CVD, only a small number of them remain adherent to medical treatment. More than fifty percent of them have uncontrolled hypertension and dyslipidemia rates, posing a significant challenge to global health<sup><xref rid="B28" ref-type="bibr">28</xref></sup><sup>,</sup><sup><xref rid="B29" ref-type="bibr">29</xref></sup>. The use of a polypill seems to be an effective strategy to improve the rates of adequate control of cardiovascular risk factors and reduce cardiovascular mortality by simplifying medication therapy<sup><xref rid="B29" ref-type="bibr">29</xref></sup>.</p><p>The polypill-based strategy showed positive effects on lipid profile enhancement<sup><xref rid="B30" ref-type="bibr">30</xref></sup><sup>,</sup><sup><xref rid="B31" ref-type="bibr">31</xref></sup>. Better lipid profile control was achieved in patients treated with the polypill in our study. This finding was in line with a retrospective observational study of 6,117 patients with IHD, which showed a greater reduction in LDL-C in patients treated with the CNIC polypill<sup><xref rid="B32" ref-type="bibr">32</xref></sup>. It was also demonstrated in the Bacus study that the CV polypill for secondary prevention enhances lipid profile control regardless of the patient&#8217;s BMI<sup><xref rid="B33" ref-type="bibr">33</xref></sup>.</p><p>The FOCUS project identified several factors that predicted non-adherence to polypill medication, including age under 50, depression, low social support, low insurance coverage, and treatment complexity<sup><xref rid="B34" ref-type="bibr">34</xref></sup>. Our study expanded on these findings by adding a history of CKD, a history of cerebrovascular disease, EF, WC, and in-hospital complications as additional predictors of medication adherence. </p><p>Patients with CKD have been shown to have poor medication adherence in previous studies. The high cost of treatment, fear of drug interactions, concerns about multi-drug treatment, and doubts about the real efficacy of some prescribed drugs may explain non-adherence among CKD patients<sup><xref rid="B35" ref-type="bibr">35</xref></sup><sup>,</sup><sup><xref rid="B36" ref-type="bibr">36</xref></sup>. Furthermore, Tanashyan et al. demonstrated inadequate adherence to treatment among patients with cerebrovascular disease. Factors contributing to this condition include cognitive impairment, a higher number of prescribed medications, and the presence of comorbid conditions such as diabetes mellitus and hypertension<sup><xref rid="B37" ref-type="bibr">37</xref></sup>. Our findings are consistent with prior research, suggesting that comorbidities such as CKD and cerebrovascular disease may increase the probability of medication non-adherence<sup><xref rid="B38" ref-type="bibr">38</xref></sup><sup>,</sup><sup><xref rid="B39" ref-type="bibr">39</xref></sup>. We also found reduced left ventricular EF (LVEF) predicted non-adherence to the polypill strategy. LVEF is a powerful predictor of poor outcomes in patients with STEMI, and patients with lower LVEF are at high risk of mortality<sup><xref rid="B40" ref-type="bibr">40</xref></sup><sup>,</sup><sup><xref rid="B41" ref-type="bibr">41</xref></sup>. </p><p>The likelihood of medication adherence was higher in patients with in-hospital complications such as atrial tachyarrhythmia and bleeding. It appears that patients who experience complications during their hospital stay are more likely to accept prescribed medication. This is because they want to reduce the risk of re-hospitalization and prevent the recurrence of adverse events.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline Characteristics of Study Participants in Polypill and Usual Care Groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Characteristics</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1">
<bold>
<italic toggle="yes">Polypill group</italic>
</bold>
<break/>
<bold>
<italic toggle="yes">n=289</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Usual care group</italic>
</bold>
<break/>
<bold>
<italic toggle="yes">n=335</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Total</italic>
</bold>
<break/>
<bold>
<italic toggle="yes">n=624</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P value</italic>
</bold>
</th></tr></thead><tbody><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Age (years), Mean (SD)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">61.67(8.54)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">62.10(9.63)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">61.90(9.14)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.576</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Male, n (%)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">229(79.20)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">277(82.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">506(81.10)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.160</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Married, n (%)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">265(91.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">296(88.40)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">561(90.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.103</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Educational Levels, n (%)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0-5 Years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">69(23.90)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">145(43.30)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">214(34.30)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="3" colspan="1">&lt;0.001</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">6-12 years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">213(73.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">140(41.80)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">353(56.60)</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&gt;12 Years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">7(2.40)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">50(14.90)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">57(9.10)</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Past Medical History, n (%)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">HTN </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">84(29.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">98(29.30)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">182(29.20)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.487</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">DM </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">75(25.90)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">93(27.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">168(26.90)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.351</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Dyslipidemia </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">86(29.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">111(33.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">197(31.60)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.221</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cerebrovascular disease </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">7(2.40)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">12(3.50)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">19(2.90)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.324</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">CKD</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">5(1.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">3(0.90)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">8(1.20)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.363</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Clinical Manifestation, Mean (SD)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">WC (cm)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">100.60(11.62)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">93.39(17.40)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">96.73(15.42)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">EF</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">39.25(7.46)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">38.91(9.82)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">39.07(8.80)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.300</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Family History, n (%)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">HTN</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">125(43.30)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">160(47.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">285(45.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.164</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">DM</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">118(40.80)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">126(37.60)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">244(39.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.237</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Dyslipidemia</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">94(32.50)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">108(32.20)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">202(32.40)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.511</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">MI</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">162(56.10)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">172(51.40)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">334(53.50)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.135</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Laboratory Data, Mean (SD)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">LDL-C (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">101.86(22.34)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">106.54(26.40)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">104.37(24.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.028</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">HDL-C (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">41.09(7.97)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">39.38(6.82)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">40.17(7.42)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">TG (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">149.71(60.12)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">147.26(68.94)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">148.39(64.97)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.301</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cholesterol (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">175.60(44.33)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">176.15(28.42)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">175.90(36.62)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.156</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Creatinine (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.03(0.52)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">1.07(0.21)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.05(0.38)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Type of Treatment, n (%)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Primary PCI &amp; CABG</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">277 (95.80)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">326 (97.30)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">589 (96.40)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.101</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Thrombolysis </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">2(0.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">9(2.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">11(1.80)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.055</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">In-Hospital Complications, n (%)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Atrial tachyarrhythmia </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0(0.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">4(1.19)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">4(0.64)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Ventricular tachyarrhythmia </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0(0.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">12(3.60)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">12(1.92)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.151</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Bleeding </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">5(1.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">2(0.60)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">7(1.20)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.399</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">AF</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0(0.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" colspan="2" rowspan="1">11(3.30)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">11(1.80)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.582</td></tr></tbody></table><table-wrap-foot><p>SD: Standard Deviation, HTN: Hypertension, DM: Diabetes Mellitus, CKD: Chronic Kidney Disease, WC: Waist Circumference, EF: Ejection Fraction, MI: Myocardial Infarction, LDL-C: Low-density Lipoprotein Cholesterol, HDL-C: High-density Lipoprotein Cholesterol, TG: Triglyceride, PCI: Percutaneous Intervention, CABG: Coronary Artery Bypass Graft, AF: Atrial Fibrillation. P value &lt; 0.05 is significant.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Comparison of Patient Satisfaction and Lipid Profile between Polypill and Usual Care Groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Polypill group</italic>
</bold>
<break/>
<bold>
<italic toggle="yes">n=289</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Usual care group</italic>
</bold>
<break/>
<bold>
<italic toggle="yes">n=335</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Total</italic>
</bold>
<break/>
<bold>
<italic toggle="yes">n=624</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P value</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Treatment effect</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1">
<bold>
<italic toggle="yes">95% CI</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P value</italic>
</bold>
</th></tr><tr><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Patient Satisfaction</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">TSQM domain, Mean (SD)</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> Effectiveness</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">8.94(0.36)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">8.87(0.74)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">8.90(0.60)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.681</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.016</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.998</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.034</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.081</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> Adverse effects</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">5.65(6.06)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">2.95(2.75)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">4.20(4.78)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.947</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.922</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.973</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> Convenience</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">13.15(1.78)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">12.23(1.45)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">12.72(1.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.978</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.935</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.989</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.007</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> Global satisfaction</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">13.06(1.97)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">12.75(1.18)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">12.92(1.66)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.001</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.986</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.945</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.995</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.034</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Lipid Profile</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cholesterol (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">144.57 (26.86)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">144.19 (41.60)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">144.37 (35.51)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.808</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.001</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.000</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.002</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.081</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">LDL-C (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">77.06 (17.31)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">82.89 (58.01)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">80.19 (44.17)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.043</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.002</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.000</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.004</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.018</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">HDL-C (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">41.40 (19.90)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">37.92 (7.6)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">39.78 (15.56)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.997</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.991</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.999</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.007</td></tr></tbody></table><table-wrap-foot><p>TSQM: Treatment Satisfaction Questionnaire for Medication, LDL-C: Low-density Lipoprotein Cholesterol, HDL-C: High-density Lipoprotein Cholesterol, SD: Standard Deviation, CI: Confidence Interval. P value &lt; 0.05 is significant.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Characteristics of study participants based on adherence levels.</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Characteristics</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Non-Adherence</italic>
</bold>
<break/>
<bold>
<italic toggle="yes">n=377</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Good-Adherence</italic>
</bold>
<break/><bold><italic toggle="yes">n=247</italic></bold></th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Total</italic>
</bold>
<break/>
<bold>
<italic toggle="yes">n=624</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P value</italic>
</bold>
</th></tr></thead><tbody><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Age (years)</italic>
</bold>
<bold>
<italic toggle="yes">, Mean (SD)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">61.77(9.12)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">63.55(9.25)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">61.90(9.14)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.130</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Male, n (%)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">306(81.16)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">200(80.97)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">506(81.08)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.546</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Married, n (%)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">341(90.45)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">205(83.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">546(87.50)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.150</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Educational Levels, n (%)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0-5 Years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">129(34.21)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">85(34.41)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">214(34.30)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="3" colspan="1">0.658</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">6-12 years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">221(58.62)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">79(31.98)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">300(48.08)</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&gt;12 Years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">26(6.89)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">84(34.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">110(17.62)</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Past Medical History, n (%)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> HTN </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">108(28.64)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">84(34.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">192(30.77)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.281</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> DM </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">99(26.25)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">84(34.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">183(29.32)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.171</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Dyslipidemia </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">119(31.56)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">73(29.55)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">192(30.76)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.454</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cerebrovascular disease </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">90(23.87)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">26(10.52)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">116(18.58)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.031</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">CKD</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">34(9.01)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">16(6.47)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">50(8.01)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Clinical Manifestation, Mean (SD)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">WC (cm)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">96.79(15.45)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">96.02(15.13)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">96.73(15.42)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.481</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">EF </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">39.22(8.85)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">37.17(7.99)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">39.07(8.80)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.091</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Family History, n (%)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">HTN</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">173(45.88)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">105(42.51)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">278(44.55)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.544</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">DM</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">145(38.46)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">110(44.53)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">255(40.86)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.329</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Dyslipidemia</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">120(31.83)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">95(38.46)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">215(34.45)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.221</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">MI</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">197(52.25)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">163(66.00)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">360(57.69)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.059</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Laboratory Data, Mean (SD)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">LDL-C (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">103.99(24.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">109.06(24.50)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">104.37(24.70)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.135</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">HDL-C (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">40.14(7.48)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">40.63(6.58)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">40.17(7.42)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.891</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">TG (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">147.93(65.20)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">154.05(62.35)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">148.39(64.97)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.902</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cholesterol (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">175.38(36.75)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">182.12(34.77)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">175.90(36.62)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.156</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Creatinine (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.05(0.39)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.09(0.18)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.05(0.38)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.027</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Type of Treatment, n (%)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Primary PCI &amp; CABG</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">361 (97.34)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">241 (97.57)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">602 (96.47)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.497</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Thrombolysis </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">6(1.59)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">5(2.02)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">11(1.76)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.582</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">In-Hospital Complications, n (%)</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Atrial tachyarrhythmia </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1(0.26)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 16(6.47)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">17(2.72)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.022</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Ventricular tachyarrhythmia </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">11(2.91)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">10(4.04)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">21(3.36)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.652</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Bleeding </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1(0.26)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">26(10.52)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">27(4.30)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.022</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">AF</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">6(1.59)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">11(4.45)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">17(2.72)</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.486</td></tr></tbody></table><table-wrap-foot><p>SD: Standard Deviation, HTN: Hypertension, DM: Diabetes Mellitus, CKD: Chronic Kidney Disease, WC: Waist Circumference, EF: Ejection Fraction, MI: Myocardial Infarction, LDL-C: Low-density Lipoprotein Cholesterol, HDL-C: High-density Lipoprotein Cholesterol, TG: Triglyceride, PCI: Percutaneous Intervention, CABG: Coronary Artery Bypass Graft, CHF: Congestive Heart Failure, AF: Atrial Fibrillation. P value &lt; 0.05 is significant.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Multivariable analysis in determining factors associated with medication adherence (age and sex-adjusted).</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Characteristics</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">OR*</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" colspan="2" rowspan="1">
<bold>
<italic toggle="yes">95% CI</italic>
</bold>
</th><th style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P value</italic>
</bold>
</th></tr></thead><tbody><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Married</italic>
</bold>
<bold><italic toggle="yes">(vs. other marital status)</italic></bold></td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.446</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.608</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">3.438</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.404</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Educational Levels</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0-5 Years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">Ref.</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">6-12 years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.331</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.715</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">2.475</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.366</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">&gt;12 Years</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.930</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.344</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">2.506</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.886</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Past Medical History</italic>
</bold>
</td><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> HTN </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.831</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.424</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.628</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.592</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> DM </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.747</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.380</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.470</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.400</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Dyslipidemia </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.215</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.611</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">2.409</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.578</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cerebrovascular disease </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">4.577</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.410</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">14.860</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">CKD</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">13.392</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">2.827</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">63.435</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Clinical Manifestation </italic>
</bold>
</td><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes"> WC (cm)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.01</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.004</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.035</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">EF</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.957</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.930</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.984</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Family History</italic>
</bold>
</td><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">HTN</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.239</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.683</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">2.247</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.479</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">DM</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.976</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.535</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.782</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.938</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Dyslipidemia</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.904</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.489</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.672</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.751</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">MI</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.740</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.413</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.362</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.346</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Laboratory Data</italic>
</bold>
</td><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">LDL-C (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.996</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.986</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.006</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.482</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">HDL-C (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.968</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.934</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.003</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.076</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">TG (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.999</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.994</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.004</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.632</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Cholesterol (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.996</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.989</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.003</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.297</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Creatinine (mg/dl)</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.842</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.308</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">2.296</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.736</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Type of Treatment</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Primary PCI &amp; CABG</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.542</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.212</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">1.386</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.201</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Thrombolysis</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.859</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.106</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">6.896</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.886</td></tr><tr><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">In-Hospital Complications</italic>
</bold>
</td><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#C00000; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Atrial tachyarrhythmia</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.039</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.003</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.458</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.010</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Ventricular tachyarrhythmia </italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.903</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.111</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">7.378</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.924</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Bleeding</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.034</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.003</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.399</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.007</td></tr><tr><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">AF</italic>
</bold>
</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.715</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.081</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.862</td><td style="background-color:#F7E4E4; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">0.763</td></tr></tbody></table><table-wrap-foot><p>*Adjusted for Sex and Age. OR: Odds Ratio, CI: Confidence Interval, HTN: Hypertension, DM: Diabetes Mellitus, CKD: Chronic Kidney Disease, WC: Waist Circumference, EF: Ejection Fraction, MI: Myocardial Infarction, LDL-C: Low-density Lipoprotein Cholesterol, HDL-C: High-density Lipoprotein Cholesterol, TG: Triglyceride, PCI: Percutaneous Intervention, CABG: Coronary Artery Bypass Graft, CHF: Congestive Heart Failure, AF: Atrial Fibrillation. P value &lt; 0.05 is significant. </p></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions"><title>Conclusions</title><p>According to our results, in STEMI, using the polypill-based approach showed a similar one-year medication adherence rate versus usual care, despite increased patient satisfaction and lipid profile improvement. We also identified CKD, cerebrovascular disease, EF, WC, and in-hospital complications as medication adherence predictors.</p><sec><title>Strength and Limitations</title><p>This study was the first to assess the effect of the polypill as a secondary prevention strategy on medication adherence, satisfaction, and CV risk factors in a large cohort of STEMI patients, which is a clear strength of the study. However, our analysis has some limitations. Firstly, the follow-up duration was relatively short, and an extended follow-up period is essential to evaluate a more comprehensive analysis of the impact of polypills on medication adherence in this subgroup. Secondly, we were unable to find a reasonable explanation for the significant correlation between waist circumference and medication adherence. Third, 81 percent of participants were male and the results of the study may not be generalized. Given these limitations, the results should be interpreted with caution.</p></sec></sec></body><back><ack><title>Acknowledgment</title><p>We express our gratitude toward Isfahan Cardiovascular Research Institute and Cardiac Rehabilitation Research Center staff for their kind help. The main research (Persian Polypill Study) was supported by the Grant Committee under award number [962502] from the National Institute for Medical Research Development (NIMAD), Tehran, Iran.</p></ack><sec sec-type="COI-statement"><title>Conflict of interests</title><p>All authors declare that there is no conflict of interest. </p></sec><sec><title>Funding</title><p>
<funding-source>The present research was supported by the Research Council of Isfahan University of Medical Sciences as a residency thesis number [3402636]. </funding-source>
</p></sec><sec><title>Author&#8217;s Contributions</title><p>Conceptualization: MS, ShG, HR; Data Curation: EA, AA, MKA, ZTJ, JN, HS, AKF, MA, KH; Formal Analysis: HR, MM; Funding Acquisition: MS, EA, ESh, ShG; Investigation: MS, Esh; Methodology: MS, HR, ShG, AN; Supervision: MS, ESh, MA; Validation: MS, HR; Writing, Review, Editing &amp; Final approval: all of the authors.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>RD</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>RA</given-names></name></person-group><article-title>Diagnosis and Treatment of Acute Coronary Syndromes: A Review</article-title><source> JAMA</source><year>2022</year><month>Feb</month><day>15</day><volume>327</volume><issue>7</issue><fpage>662</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">35166796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2022.0358</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kingma</surname><given-names>J</given-names></name></person-group><article-title>Myocardial infarction: An overview of STEMI and NSTEMI physiopathology and treatment</article-title><source> World J Cardiovasc Dis</source><year>2018</year><volume>8</volume><issue>11</issue><fpage>498</fpage><lpage>517</lpage></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varwani</surname><given-names>M</given-names></name><name name-style="western"><surname>Ngunga</surname><given-names>M</given-names></name><name name-style="western"><surname>Jeilan</surname><given-names>M</given-names></name><etal/></person-group><article-title>ST-Segment Elevation Myocardial Infarction (STEMI): A 10-year Review form a primary PCI capable hospital in Tanzania</article-title><source> Res Square</source><year>2024 </year><pub-id pub-id-type="doi" assigning-authority="pmc">10.11604/pamj.2024.49.82.45351</pub-id><pub-id pub-id-type="pmcid">PMC11871888</pub-id><pub-id pub-id-type="pmid">40027086</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>S</given-names></name><name name-style="western"><surname>Rosengren</surname><given-names>A</given-names></name><name name-style="western"><surname>Young</surname><given-names>K</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>E</given-names></name></person-group><article-title>Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review</article-title><source> BMC Cardiovasc Disord</source><year>2017</year><month>Feb</month><day>7</day><volume>17</volume><issue>1</issue><fpage>53 </fpage><pub-id pub-id-type="pmid">28173750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12872-017-0482-9</pub-id><pub-id pub-id-type="pmcid">PMC5297173</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figtree</surname><given-names>GA</given-names></name><name name-style="western"><surname>Vernon</surname><given-names>ST</given-names></name><name name-style="western"><surname>Hadziosmanovic</surname><given-names>N</given-names></name><etal/></person-group><article-title>Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data</article-title><source> Lancet</source><year>2021</year><volume>397</volume><issue>10279</issue><fpage>1085</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">33711294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00272-5</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visseren</surname><given-names>FLJ</given-names></name><name name-style="western"><surname>Mach</surname><given-names>F</given-names></name><name name-style="western"><surname>Smulders</surname><given-names>YM</given-names></name><name name-style="western"><surname>Carballo</surname><given-names>D</given-names></name><name name-style="western"><surname>Koskinas</surname><given-names>KC</given-names></name><name name-style="western"><surname>B&#228;ck</surname><given-names>M</given-names></name><etal/></person-group><article-title>2021 ESC Guidelines on cardiovascular disease prevention in clinical practice</article-title><source> Eur Heart J</source><year>2021</year><month>Sep</month><day>7</day><volume>42</volume><issue>34</issue><fpage>3227</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">34458905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehab484</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahhal</surname><given-names>A</given-names></name><name name-style="western"><surname>Mahfouz</surname><given-names>A</given-names></name><name name-style="western"><surname>Khir</surname><given-names>F</given-names></name><name name-style="western"><surname>Okleh</surname><given-names>N</given-names></name><name name-style="western"><surname>Aljundi</surname><given-names>AH</given-names></name><name name-style="western"><surname>AlKhalaila</surname><given-names>O</given-names></name><etal/></person-group><article-title>Medications adherence post-primary percutaneous coronary intervention in acute myocardial infarction: A population-based cohort study</article-title><source> J Clin Pharm Ther</source><year>2021</year><month>Jun</month><volume>46</volume><issue>3</issue><fpage>772</fpage><pub-id pub-id-type="pmid">33382471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcpt.13348</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korol</surname><given-names>S</given-names></name><name name-style="western"><surname>Ws&#243;&#322;</surname><given-names>A</given-names></name><name name-style="western"><surname>Puchalska</surname><given-names>L</given-names></name><name name-style="western"><surname>Reshetnik</surname><given-names>A</given-names></name></person-group><article-title>Medication adherence and its impact on the average life expectancy after st-segment elevation myocardial infarction: the results of the Ukrainian stimul registry</article-title><source> Wiad Lek</source><month>2022</month><volume>75</volume><issue>3</issue><fpage>563</fpage><pub-id pub-id-type="pmid">35522859</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malachias</surname><given-names>MVB</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>SE</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>DCd</given-names></name><name name-style="western"><surname>Brand&#227;o</surname><given-names>AA</given-names></name><name name-style="western"><surname>Sposito</surname><given-names>AC</given-names></name><name name-style="western"><surname>Moura</surname><given-names>LZ</given-names></name><etal/></person-group><article-title>Risk of Adverse Health Outcomes in Patients with Poor Adherence to Cardiovascular Medication Treatment: a Systematic Review</article-title><year>SciELO</year><comment>Preprint</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.36660/abc.20240469</pub-id><pub-id pub-id-type="pmcid">PMC11634203</pub-id><pub-id pub-id-type="pmid">39607399</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kengne</surname><given-names>AP</given-names></name><name name-style="western"><surname>Bri&#232;re</surname><given-names>JB</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>MK</given-names></name><name name-style="western"><surname>Atanasov</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review</article-title><source> Expert Rev Pharmacoecon Outcomes Res</source><year>2024</year><month>Jan</month><volume>24</volume><issue>1</issue><fpage>143</fpage><pub-id pub-id-type="pmid">37862440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737167.2023.2266135</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wald</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Law</surname><given-names>MR</given-names></name></person-group><article-title>A strategy to reduce cardiovascular disease by more than 80%</article-title><source> BMJ</source><year>2003</year><month>Jun</month><day>28</day><volume>326</volume><issue>7404</issue><lpage>1419</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.326.7404.1419</pub-id><pub-id pub-id-type="pmcid">PMC162259</pub-id><pub-id pub-id-type="pmid">12829553</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Cass</surname><given-names>A</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>D</given-names></name><name name-style="western"><surname>Usherwood</surname><given-names>T</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A</given-names></name><name name-style="western"><surname>Jan</surname><given-names>S</given-names></name><etal/></person-group><article-title>A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk</article-title><source> Eur J Prev Cardiol</source><year>2015</year><month>Jul</month><volume>22</volume><issue>7</issue><fpage>920</fpage><pub-id pub-id-type="pmid">24676715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2047487314530382</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webster</surname><given-names>R</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Selak</surname><given-names>V</given-names></name><name name-style="western"><surname>Billot</surname><given-names>L</given-names></name><name name-style="western"><surname>Bots</surname><given-names>ML</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effectiveness of fixed dose combination medication (&#8216;polypills&#8217;) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries</article-title><source> Int J Cardiol</source><year>2016</year><month>Feb</month><day>15</day><volume>205</volume><fpage>147</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">26736090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2015.12.015</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thom</surname><given-names>S</given-names></name><name name-style="western"><surname>Field</surname><given-names>J</given-names></name><name name-style="western"><surname>Poulter</surname><given-names>N</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Prabhakaran</surname><given-names>D</given-names></name><name name-style="western"><surname>Stanton</surname><given-names>A</given-names></name><etal/></person-group><article-title>Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe</article-title><source> Eur J Prev Cardiol</source><year>2014</year><month>Feb</month><volume>21</volume><issue>2</issue><fpage>252</fpage><pub-id pub-id-type="pmid">23038750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2047487312463278</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selak</surname><given-names>V</given-names></name><name name-style="western"><surname>Elley</surname><given-names>CR</given-names></name><name name-style="western"><surname>Crengle</surname><given-names>S</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>M</given-names></name><name name-style="western"><surname>Doughty</surname><given-names>R</given-names></name><name name-style="western"><surname>Arroll</surname><given-names>B</given-names></name><etal/></person-group><article-title>IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care</article-title><source> Contemp Clin Trials</source><year>2011</year><month>Nov</month><volume>32</volume><issue>6</issue><fpage>909</fpage><pub-id pub-id-type="pmid">21777702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cct.2011.07.006</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names>M</given-names></name><name name-style="western"><surname>Askari</surname><given-names>A</given-names></name><name name-style="western"><surname>Bostan</surname><given-names>F</given-names></name><name name-style="western"><surname>Heidari</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>G</given-names></name><name name-style="western"><surname>Alavi</surname><given-names>Tabatabaei G</given-names></name><etal/></person-group><article-title>Medication Adherence With Polypill in Cardiovascular Disease and High-Risk Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Involving 7364 Participants</article-title><source> Curr Probl Cardiol</source><year>2024</year><month>Jan</month><volume>49</volume><issue>1 Pt A</issue><fpage>102061</fpage><pub-id pub-id-type="pmid">37640178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpcardiol.2023.102061</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosin-Sales</surname><given-names>J</given-names></name><name name-style="western"><surname>Murcia-Zaragoza</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pereyra-Rico</surname><given-names>HO</given-names></name><name name-style="western"><surname>de</surname><given-names>la Guia-Galipienso F</given-names></name><name name-style="western"><surname>Hermans</surname><given-names>K</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>G</given-names></name></person-group><article-title>PCV135 observational, international, cohort study to evaluate the satisfaction and preferences of patients in preventive treatment of secondary cardiovascular events with a cardiovascular polypill</article-title><source> Value Health</source><year>2019</year><fpage> S566</fpage><lpage>7</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>RA</given-names></name><name name-style="western"><surname>Rossello</surname><given-names>X</given-names></name><name name-style="western"><surname>Coughlan</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Barbato</surname><given-names>E</given-names></name><name name-style="western"><surname>Berry</surname><given-names>C</given-names></name><name name-style="western"><surname>Chieffo</surname><given-names>A</given-names></name><etal/></person-group><article-title>2023 ESC Guidelines for the management of acute coronary syndromes</article-title><source> Eur Heart J</source><year>2023</year><month>Oct</month><day>12</day><volume>44</volume><issue>38</issue><fpage>3720</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">37622654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad191</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>RM</given-names></name><name name-style="western"><surname>Badano</surname><given-names>LP</given-names></name><name name-style="western"><surname>Mor-Avi</surname><given-names>V</given-names></name><name name-style="western"><surname>Afilalo</surname><given-names>J</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>A</given-names></name><name name-style="western"><surname>Ernande</surname><given-names>L</given-names></name><etal/></person-group><article-title>Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</article-title><source> J Am Soc Echocardiogr</source><year>2015</year><month>Jan</month><volume>28</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="pmid">25559473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.echo.2014.10.003</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghobadi</surname><given-names>P</given-names></name><name name-style="western"><surname>Gholami</surname><given-names>M</given-names></name><name name-style="western"><surname>Hasanvand</surname><given-names>S</given-names></name><name name-style="western"><surname>Toulabi</surname><given-names>T</given-names></name><name name-style="western"><surname>Moradifar</surname><given-names>N</given-names></name><name name-style="western"><surname>Birjandi</surname><given-names>M</given-names></name></person-group><article-title>Effects of a multidisciplinary management program on symptom burden and medication adherence in heart failure patients with comorbidities: A randomized controlled trial</article-title><source> BMC Nurs</source><year>2022</year><month>Dec</month><day>7</day><volume>21</volume><issue>1</issue><fpage>346 </fpage><pub-id pub-id-type="pmid">36476375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12912-022-01130-7</pub-id><pub-id pub-id-type="pmcid">PMC9727875</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdshah</surname><given-names>A</given-names></name><name name-style="western"><surname>Parsaeian</surname><given-names>M</given-names></name><name name-style="western"><surname>Nasimi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghiasi</surname><given-names>M</given-names></name></person-group><article-title>Validating the &#8220;Treatment Satisfaction Questionnaire for Medication&#8221; in Persian and Evaluating Treatment Satisfaction Among Patients With Psoriasis</article-title><source> Value Health Reg Issues</source><year>2022 </year><fpage> 16</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">34800824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vhri.2021.06.008</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellano</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pocock</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><name name-style="western"><surname>Quesada</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Owen</surname><given-names>R</given-names></name><name name-style="western"><surname>Fernandez-Ortiz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Polypill Strategy in Secondary Cardiovascular Prevention</article-title><source> N Engl J Med</source><year>2022</year><month>Sep</month><day>15</day><volume>387</volume><issue>11</issue><fpage>967</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">36018037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2208275</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villalobos-Pedroza</surname><given-names>M</given-names></name><name name-style="western"><surname>Hernandez-Pastrana</surname><given-names>S</given-names></name><name name-style="western"><surname>Arias-Mendoza</surname><given-names>A</given-names></name><name name-style="western"><surname>Latapi-Ruiz</surname><given-names>Esparza X</given-names></name><name name-style="western"><surname>Robles-Ledesma</surname><given-names>M</given-names></name><name name-style="western"><surname>Guerrero-Ochoa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Adherence to optimal medical therapy and control of cardiovascular risk factors in patients after ST elevation myocardial infarction in Mexico</article-title><source> Front Cardiovasc Med</source><year>2024</year><month>Jul</month><day>23</day><volume>11</volume><fpage>1384684</fpage><pub-id pub-id-type="pmid">39114561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2024.1384684</pub-id><pub-id pub-id-type="pmcid">PMC11304054</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hoseini</surname><given-names>SG</given-names></name><name name-style="western"><surname>Nateghi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sarrafzadegan</surname><given-names>N</given-names></name><name name-style="western"><surname>Mansoorian</surname><given-names>M</given-names></name><name name-style="western"><surname>Najafian</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, A Randomized Clinical Trial</article-title><source> Curr Probl Cardiol</source><year>2022</year><month>Jun</month><volume>47</volume><issue>6</issue><fpage>100872</fpage><pub-id pub-id-type="pmid">34016484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpcardiol.2021.100872</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosin-Sales</surname><given-names>J</given-names></name><name name-style="western"><surname>Murcia-Zaragoza</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pereyra-Rico</surname><given-names>HO</given-names></name><name name-style="western"><surname>la</surname><given-names>Gu&#237;a-Galipienso F</given-names></name><name name-style="western"><surname>Hermans</surname><given-names>K</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>G</given-names></name></person-group><article-title>Evaluating patients&#8217; satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study</article-title><source> J Comp Eff Res</source><year>2021</year><month>Sep</month><volume>10</volume><issue>13</issue><fpage>975</fpage><pub-id pub-id-type="pmid">34196593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/cer-2021-0105</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>KK</given-names></name><name name-style="western"><surname>Rafiq</surname><given-names>T</given-names></name></person-group><article-title>Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries</article-title><source> Can J Cardiol</source><year>2021</year><month>May</month><volume>37</volume><issue>5</issue><fpage>733</fpage><pub-id pub-id-type="pmid">33610690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cjca.2021.02.009</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L</given-names></name></person-group><article-title>Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies</article-title><source> BMC Cardiovasc Disord</source><year>2021</year><month>Feb</month><day>3</day><volume>21</volume><issue>1</issue><fpage>69 </fpage><pub-id pub-id-type="pmid">33535982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12872-020-01835-0</pub-id><pub-id pub-id-type="pmcid">PMC7860615</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>GC</given-names></name><name name-style="western"><surname>Han</surname><given-names>JK</given-names></name><name name-style="western"><surname>Han</surname><given-names>KH</given-names></name><name name-style="western"><surname>Hyon</surname><given-names>MS</given-names></name><name name-style="western"><surname>Doh</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study</article-title><source> Clin Ther</source><year>2018</year><month>May</month><volume>40</volume><issue>5</issue><fpage>676</fpage><pub-id pub-id-type="pmid">29673890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2018.03.010</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de</surname><given-names>Abreu-Silva EO</given-names></name><name name-style="western"><surname>Siepmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Siepmann</surname><given-names>T</given-names></name></person-group><article-title>Polypills in the Management of Cardiovascular Risk-A Perspective</article-title><source> J Clin Med</source><year>2024</year><month>Sep</month><day>16</day><volume>13</volume><issue>18</issue><fpage>5487</fpage><pub-id pub-id-type="pmid">39336974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13185487</pub-id><pub-id pub-id-type="pmcid">PMC11432011</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivera</surname><given-names>A</given-names></name><name name-style="western"><surname>Campos</surname><given-names>B</given-names></name><name name-style="western"><surname>Ceolin</surname><given-names>S</given-names></name><name name-style="western"><surname>Godoi</surname><given-names>A</given-names></name><name name-style="western"><surname>Castanha</surname><given-names>E</given-names></name><name name-style="western"><surname>Campello</surname><given-names>Jorge CA</given-names></name><etal/></person-group><article-title>Polypill-based strategy vs usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials</article-title><source> Eur J Prev Cardiol</source><year>2023</year><month>Nov</month><day>9</day><volume>30</volume><issue>16</issue><fpage>1828</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">37490769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurjpc/zwad245</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennawi</surname><given-names>HA</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>MT</given-names></name><name name-style="western"><surname>Zohaib</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MK</given-names></name><name name-style="western"><surname>Khan</surname><given-names>IA</given-names></name><name name-style="western"><surname>Muhammadzai</surname><given-names>HZU</given-names></name><etal/></person-group><article-title>Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials</article-title><source> Curr Probl Cardiol</source><year>2023</year><month>Aug</month><volume>48</volume><issue>8</issue><fpage>101735</fpage><pub-id pub-id-type="pmid">37044270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpcardiol.2023.101735</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalmau</surname><given-names>R</given-names></name><name name-style="western"><surname>Cordero</surname><given-names>A</given-names></name><name name-style="western"><surname>Masana</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>E</given-names></name><name name-style="western"><surname>Sicras-Mainar</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Juanatey</surname><given-names>JR</given-names></name></person-group><article-title>The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease</article-title><source> Eur Heart J Open</source><year>2024</year><month>Apr</month><day>2</day><volume>4</volume><issue>2</issue><fpage>oeae027</fpage><pub-id pub-id-type="pmid">38686352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ehjopen/oeae027</pub-id><pub-id pub-id-type="pmcid">PMC11056486</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ch&#225;vez</surname><given-names>Fern&#225;ndez JA</given-names></name><name name-style="western"><surname>Ram&#237;rez</surname><given-names>Mendoza M</given-names></name><name name-style="western"><surname>Kassck</surname><given-names>Ipinaa H</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>&#193;ngeles LA</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>Ch&#225;vez A</given-names></name><name name-style="western"><surname>Escobedo</surname><given-names>G</given-names></name><name name-style="western"><surname>M&#233;ndez-Garc&#237;a</surname><given-names>LA</given-names></name></person-group><article-title>The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease The Bacus study</article-title><source> PLoS One</source><year>2023</year><month>Aug</month><day>25</day><volume>18</volume><issue>8</issue><lpage>e0290544</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0290544</pub-id><pub-id pub-id-type="pmcid">PMC10456133</pub-id><pub-id pub-id-type="pmid">37624820</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellano</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>G</given-names></name><name name-style="western"><surname>Pe&#241;alvo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bansilal</surname><given-names>S</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Ortiz</surname><given-names>A</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>L</given-names></name><etal/></person-group><article-title>A polypill strategy to improve adherence: results from the FOCUS project</article-title><source> J Am Coll Cardiol</source><year>2014</year><month>Nov</month><day>18-25</day><volume>64</volume><issue>20</issue><fpage>2071</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">25193393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2014.08.021</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>D</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>H</given-names></name><name name-style="western"><surname>Meel</surname><given-names>S</given-names></name></person-group><article-title>Assessment of medication adherence in chronic kidney disease patients: a tertiary care experience</article-title><source> Int J Health Sci Res</source><day>2018</day><volume>8</volume><issue>11</issue><fpage>20</fpage><lpage>30</lpage></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnier</surname><given-names>M</given-names></name><name name-style="western"><surname>Pruijm</surname><given-names>M</given-names></name><name name-style="western"><surname>Wuerzner</surname><given-names>G</given-names></name><name name-style="western"><surname>Santschi</surname><given-names>V</given-names></name></person-group><article-title>Drug adherence in chronic kidney diseases and dialysis</article-title><source> Nephrol Dial Transplant</source><year>2015</year><month>Jan</month><volume>30</volume><issue>1</issue><fpage>39</fpage><pub-id pub-id-type="pmid">24516224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfu015</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanashyan</surname><given-names>M</given-names></name><name name-style="western"><surname>Antonova</surname><given-names>K</given-names></name><name name-style="western"><surname>Lagoda</surname><given-names>O</given-names></name><name name-style="western"><surname>Kornilova</surname><given-names>A</given-names></name><name name-style="western"><surname>Shchukina</surname><given-names>E</given-names></name></person-group><article-title>Adherence to treatment in patients with cerebrovascular disease as a multifactorial problem</article-title><source> Neurol Neuropsychiatr Psychosom</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>18</fpage><lpage>27</lpage></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kvarnstr&#246;m</surname><given-names>K</given-names></name><name name-style="western"><surname>Westerholm</surname><given-names>A</given-names></name><name name-style="western"><surname>Airaksinen</surname><given-names>M</given-names></name><name name-style="western"><surname>Liira</surname><given-names>H</given-names></name></person-group><article-title>Factors Contributing to Medication Adherence in Patients with a Chronic Condition: A Scoping Review of Qualitative Research</article-title><source> Pharmaceutics</source><year>2021</year><month>Jul</month><day>20</day><volume>13</volume><issue>7</issue><fpage>1100</fpage><pub-id pub-id-type="pmid">34371791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13071100</pub-id><pub-id pub-id-type="pmcid">PMC8309154</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giacobbe</surname><given-names>F</given-names></name><name name-style="western"><surname>Giannino</surname><given-names>G</given-names></name><name name-style="western"><surname>Annone</surname><given-names>U</given-names></name><name name-style="western"><surname>Morena</surname><given-names>A</given-names></name><name name-style="western"><surname>Di</surname><given-names>Vita U</given-names></name><name name-style="western"><surname>Carmagnola</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impact of statin adherence and interruption within 6&#160;months after ST-segment elevation myocardial infarction (STEMI): Results from the real-world regional registry FAST-STEMI</article-title><source> Int J Cardiol</source><year>2024</year><month>Jun</month><day>15</day><volume>405</volume><fpage>131933</fpage><pub-id pub-id-type="pmid">38437950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2024.131933</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>N</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>K</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>A</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>N</given-names></name><name name-style="western"><surname>Morita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ten-Year Mortality in Patients With ST-Elevation Myocardial Infarction</article-title><source> Am J Cardiol</source><year>2021</year><month>Jun</month><day>15</day><volume>149</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">33753036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2021.03.008</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrante</surname><given-names>G</given-names></name><name name-style="western"><surname>Barbieri</surname><given-names>L</given-names></name><name name-style="western"><surname>Sponzilli</surname><given-names>C</given-names></name><name name-style="western"><surname>Lucreziotti</surname><given-names>S</given-names></name><name name-style="western"><surname>Salerno</surname><given-names>Uriarte D</given-names></name><name name-style="western"><surname>Centola</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictors of Mortality and Long-Term Outcome in Patients with Anterior STEMI: Results from a Single Center Study</article-title><source> J Clin Med</source><year>2021</year><month>Nov</month><day>29</day><volume>10</volume><issue>23</issue><lpage>5634</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10235634</pub-id><pub-id pub-id-type="pmcid">PMC8658372</pub-id><pub-id pub-id-type="pmid">34884341</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>